The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam’s synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in ...

It was tested in a prospective, single-blind study of 200 heart patients against the standard traditional 12-lead EKG ...

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company ...